Although OriGene Technologies Inc. is profitable, it tapped private investors for $21.3 million in a series C round to give the U.S.-China play the ability to expand the commercialization of its research tools and diagnostics.

Qiming Venture Partners and Kleiner Perkins Caufield & Byers led the round that closed in March, in which existing investor IDG-Accel also participated.